MSN LABORATORIES PRIVATE LIMITED has received approval for its ANDA 204921 for lacosamide, enabling the launch of the generic version of the oral drug. This approval expands distribution options for the seizure treatment and is expected to intensify generic competition in the neuropsychiatric market.